(19)
(11) EP 2 753 642 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
13.12.2017 Bulletin 2017/50

(45) Mention of the grant of the patent:
01.03.2017 Bulletin 2017/09

(21) Application number: 12805429.3

(22) Date of filing: 06.09.2012
(51) International Patent Classification (IPC): 
C07K 14/605(2006.01)
A61K 38/26(2006.01)
(86) International application number:
PCT/EP2012/067364
(87) International publication number:
WO 2013/037690 (21.03.2013 Gazette 2013/12)

(54)

GLP-1 DERIVATIVES

GLP-1-DERIVATE

DÉRIVÉS DE GLP-1


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 06.09.2011 EP 11180265
08.09.2011 US 201161532323 P

(43) Date of publication of application:
16.07.2014 Bulletin 2014/29

(73) Proprietor: Novo Nordisk A/S
2880 Bagsværd (DK)

(72) Inventors:
  • LAU, Jesper
    DK-2880 Bagsværd (DK)
  • BLOCH, Paw
    DK-2880 Bagsværd (DK)
  • KOFOED, Jacob
    DK-2880 Bagsværd (DK)
  • GARIBAY, Patrick
    DK-2880 Bagsværd (DK)

(74) Representative: Pedersen, Karen Oestergaard et al
Novo Nordisk A/S Novo Allé
DK-2880 Bagsværd
DK-2880 Bagsværd (DK)


(56) References cited: : 
WO-A1-94/13313
US-A- 5 525 491
WO-A2-2011/080102
US-A- 5 663 907
   
  • KNUDSEN LOTTE B ET AL: "Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 43, no. 9, 4 May 2000 (2000-05-04), pages 1664-1669, XP002573413, ISSN: 0022-2623, DOI: 10.1021/JM9909645 [retrieved on 2000-04-18]
  • CHAE S Y ET AL: "The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 144, no. 1, 21 May 2010 (2010-05-21), pages 10-16, XP027036550, ISSN: 0168-3659 [retrieved on 2010-04-30]
  • GARCIA-BUSTOS J ET AL: "A BIOLOGICAL PRICE OF ANTIBIOTIC RESISTANCE: MAJOR CHANGES IN THE PEPTIDOGLYCAN STRUCTURE OF PENICILLIN-RESISTANT PNEUMOCOCCI", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 87, no. 14, 1 July 1990 (1990-07-01), pages 5415-5419, XP000138045, ISSN: 0027-8424, DOI: 10.1073/PNAS.87.14.5415
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).